|
150 |
FDA's 483 Playbook: What It Means For Pharma Outsourcing — And What It Doesn't Address
|
관리자 |
2026-05-06 |
782 |
|
149 |
All The Ways Global Biopharma Still Grapples With Annex 1
|
관리자 |
2026-05-06 |
547 |
|
148 |
The Capacity Myth—and What Actually Matters
|
관리자 |
2026-02-27 |
1,166 |
|
147 |
Process Engineering's Key Role In Sterile Injectable Facility Design
|
관리자 |
2026-02-27 |
1,122 |
|
146 |
When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
|
관리자 |
2026-02-27 |
767 |
|
145 |
How to Design Your Pharmaceutical Facility Disinfection Programme Cleanroom
|
관리자 |
2026-01-30 |
1,395 |
|
144 |
Why Use Total Organic Carbon Analysis For Cleaning Validation?
|
관리자 |
2026-01-30 |
824 |
|
143 |
Building Enterprise Resilience From QRM Signals
|
관리자 |
2026-01-30 |
865 |
|
142 |
Contamination Control Strategies In Low Bioburden Biologic Drug Substance Manufacturing
|
관리자 |
2026-01-05 |
1,354 |
|
141 |
What 2025 FDA Warning Letters Tell Us About GMP Compliance
|
관리자 |
2026-01-05 |
938 |
